Latest Administration News

Genesis Resources progresses environmental approvals for its North Macedonian Plavica project while Australian drilling at Alice Springs and Arltunga yields underwhelming copper and gold assays.

GoldArc Resources has identified multiple high-priority gold targets at its Leonora projects and secured strategic partnerships to accelerate mining development, backed by a $2.5 million cash advance facility.

E79 Gold Mines Limited reported a solid quarter with a $3.1 million equity raise, ending December 2025 with $3.58 million in cash despite ongoing operating losses.

8common Limited reported a positive EBITDA for the first half of FY26 alongside a 4% increase in SaaS revenue, supported by significant operational cost reductions and key contract renewals.

Otto Energy reported stable oil and gas production for the December quarter, supported by a strong cash position and strategic board changes. Despite a dip in oil prices, the company’s focus on cash flow and cost management positions it well for the year ahead.

FINEOS Corporation Holdings PLC reports a robust €27.8 million cash balance at the end of 2025, maintaining its FY25 revenue guidance despite seasonal cash flow dips and currency fluctuations.

Epsilon Healthcare has posted a record $2.891 million in receipts for the December 2025 quarter, nearly doubling year-on-year revenue and marking a significant turnaround with its recent ASX reinstatement.

Sheffield Resources announces the novation of a secured loan facility to a Yansteel-related party, maintaining existing terms while progressing debt restructure negotiations for Kimberley Mineral Sands.

Caspin Resources reports standout metallurgical results from its Bygoo Tin Project, alongside promising gold and PGE exploration progress, positioning the company for a dynamic 2026.

Future Metals NL has outlined strategic initiatives to enhance its flagship Panton PGM Project, leveraging rising platinum group metal prices and new processing opportunities. Key work programs and management appointments position the company for accelerated development in 2026.

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Vection Technologies has reported a remarkable quarter with a 250% jump in customer cash receipts and a landmark $7.8 million Defence order, signalling a new phase of growth and operational strength.